A shift in how clinicians screen for endometrial cancer may be on the horizon, as latest research suggests that molecular signals of the disease can be detected through a simple vaginal swab. Published in the International Journal of Gynecological Cancer, the findings point toward a future where less invasive testing could determine which patients actually require more intensive diagnostic procedures.
For many women, the path to a cancer diagnosis is defined by anxiety and physical discomfort. Endometrial cancer is the most common gynecologic malignancy in the United States and is one of the few cancers seeing a rise in mortality. The American Cancer Society estimates that in 2026, there will be more than 69,000 new cases and over 14,000 deaths.
Currently, women experiencing abnormal or postmenopausal bleeding are often referred for invasive diagnostic procedures to sample the uterus. While these procedures are necessary for a definitive diagnosis, the statistical reality is stark: fewer than one in 10 women undergoing these tests are ultimately diagnosed with cancer. This leaves tens of thousands of patients facing invasive interventions that, in the majority of cases, do not find malignancy.
Research Context: The Diagnostic Gap
The current standard of care for evaluating postmenopausal bleeding often requires direct sampling of the uterine lining. Because the vast majority of these biopsies return negative results, there is a significant clinical need for a “triage” tool—a non-invasive test that can accurately identify high-risk patients before they undergo invasive surgery.
Challenging the Necessity of Direct Sampling
The study, conducted by PinkDx, sought to challenge a long-standing assumption in gynecologic oncology: that understanding what is happening inside the uterus requires a direct sample of uterine tissue.
To test this, researchers enrolled women who were already undergoing hysterectomies. The team collected vaginal swabs and paired them with the actual tumor tissue removed during surgery. By employing whole-transcriptome sequencing and machine learning, the researchers evaluated whether the molecular signatures of endometrial cancer were present in the vaginal swabs without the need to access the uterus itself.
The results provided peer-reviewed evidence that these molecular signals are indeed detectable via a swab. “The assumption has always been that you have to sample the uterus to understand what’s happening in the uterus,” said Giulia Kennedy, PhD, co-founder and chief scientific officer of PinkDx. “Our findings challenge that assumption.”
Implications for Patient-Centered Care
If validated at scale, this approach could fundamentally change the diagnostic journey for women. Rather than moving straight to invasive sampling, a non-invasive swab could serve as an initial screen to better identify which women warrant further evaluation.
Dr. Jason Wright, chair of obstetrics and gynecology and obstetrician- and gynecologist-in-chief at Tufts Medical Center, noted that molecular insights informing treatment decisions without invasive sampling represent a significant advance toward patient-centered care.
However, the technology is not yet ready for general clinical use. PinkDx is currently advancing prospective, multi-center clinical validation studies. These studies are designed to evaluate the approach in broader, more diverse populations and to demonstrate how these molecular insights can support clinical decision-making in a real-world setting.
Understanding the Path Forward
Could a swab replace a biopsy?
Not necessarily. The goal is likely not to replace the gold-standard tissue biopsy—which is required for definitive staging and treatment planning—but to reduce the number of women who undergo unnecessary invasive procedures by filtering out those with low molecular signals of cancer.
As the medical community moves toward more precise, molecularly-driven diagnostics, the focus is shifting from the procedure to the patient. By reducing the physical and emotional burden of the diagnostic process, clinicians may be able to reach the correct diagnosis more efficiently and with less trauma to the patient.
How might a non-invasive screening process change the way women approach early symptoms of gynecologic concerns?
